Chronic liver disease (CLD) is a spectrum of hepatic morbid manifestations which last for more than six months causing progressive deterioration in liver function. CLD includes hepatitis, cirrohosis/fibrosis and malignancies of viral, metabolic and other etiology. As a major cause of morbidity and mortality, CLD has become a severely increasing global burden due to its occupancy of health resources for patient treatment. Understanding the mechanisms of its occurrence and development of CLD will help with its better prevention and treatment.
Multi-omics strategy provides a valid approach to unveil the potential mechanisms of CLD through genome, transcriptome, proteome, and metabolome. With technological development, omics assays are now widely affordable and have therefore become a preferred option for the investigation of potential targets and pathways involved in the pathogenesis of CLD. Improved algorithm guarantees integration of multi-omics data. Such integrated omics analysis provides more reliable data to inspire further validation study in vitro and in vivo. Multi-omics data also helps with better prediction of therapeutic effects of drugs and other interventions for CLD.
This Research Topic aims to collect the studies focusing on the investigation of molecular mechanisms underlying, and construction of diagnostic/prognostic models for chronic liver disease via a systems biology approach. Data can be generated from human, animals or cell lines. Data from public database with subsequent validation is also welcomed. Meanwhile, multi-omics studies on key issues in liver transplantation (marginal grafts, ABO-mismatch and recurrence of primary liver disease) are also welcome.
The potential sub-topics include, but are not limited to:
• Multi-omics studies on construction of prediction models for diagnosis, prognosis and therapeutic effect for CLD, e.g. evaluation of adverse effects of novel kinase inhibitors on anti-hepatocellular carcinoma.
• Systems biology approaches to elucidate the molecular mechanisms underlying the occurrence and development of CLD, e.g. fatty acid synthase (Fas) in the progression of non-alcoholic fatty liver disease (NAFLD).
• Precise description on the development of CLD based on sequential multi-omics analyses, e.g. comparison of multi-omic profiles of NAFLD in animal models from mild to severe stages.
Chronic liver disease (CLD) is a spectrum of hepatic morbid manifestations which last for more than six months causing progressive deterioration in liver function. CLD includes hepatitis, cirrohosis/fibrosis and malignancies of viral, metabolic and other etiology. As a major cause of morbidity and mortality, CLD has become a severely increasing global burden due to its occupancy of health resources for patient treatment. Understanding the mechanisms of its occurrence and development of CLD will help with its better prevention and treatment.
Multi-omics strategy provides a valid approach to unveil the potential mechanisms of CLD through genome, transcriptome, proteome, and metabolome. With technological development, omics assays are now widely affordable and have therefore become a preferred option for the investigation of potential targets and pathways involved in the pathogenesis of CLD. Improved algorithm guarantees integration of multi-omics data. Such integrated omics analysis provides more reliable data to inspire further validation study in vitro and in vivo. Multi-omics data also helps with better prediction of therapeutic effects of drugs and other interventions for CLD.
This Research Topic aims to collect the studies focusing on the investigation of molecular mechanisms underlying, and construction of diagnostic/prognostic models for chronic liver disease via a systems biology approach. Data can be generated from human, animals or cell lines. Data from public database with subsequent validation is also welcomed. Meanwhile, multi-omics studies on key issues in liver transplantation (marginal grafts, ABO-mismatch and recurrence of primary liver disease) are also welcome.
The potential sub-topics include, but are not limited to:
• Multi-omics studies on construction of prediction models for diagnosis, prognosis and therapeutic effect for CLD, e.g. evaluation of adverse effects of novel kinase inhibitors on anti-hepatocellular carcinoma.
• Systems biology approaches to elucidate the molecular mechanisms underlying the occurrence and development of CLD, e.g. fatty acid synthase (Fas) in the progression of non-alcoholic fatty liver disease (NAFLD).
• Precise description on the development of CLD based on sequential multi-omics analyses, e.g. comparison of multi-omic profiles of NAFLD in animal models from mild to severe stages.
